Hello! every one!

As the basic principle of immune-checkpoint blockade for cancer, re-invigoration of T cell through inhibition of PD-1-PD-L1 pathway leads to enhanced cancer-killing capabilities. Based on this, those patients who are detected with tumor-infiltrated T cells with high expression of PD-1 are viewed as candidate appropriate population for ICI. However, T cells may also become PD-1-overexpression in the process of tumor development and some therapies. Then we may call these T cells as adaptive exhausted PD-1-high T cells. My question is what is the definite difference between these two PD-1-high T cells in the TME. And furthermore, would the difference, if any, influence the efficacy of ICI or other immunotherapies.